Tirzepatide, the drug in Zepbound and Mounjaro, switched on brown fat in obese mice

Tirzepatide, the active ingredient in Eli Lilly’s Zepbound and Mounjaro, did more in obese mice than shrink their appetite: it switched on brown fat, the tissue that burns calories to make heat. The result comes from a University of Barcelona team led by Marion Peyrou, and it has been circulating again in recent weeks through news roundups of the GLP-1 field.

The study itself is not new. It appeared in the journal Biomedicine & Pharmacotherapy, volume 195, available online on January 26, 2026 and dated February 2026 in print. What follows is an explainer of what the mouse experiment did, what it found, and why its authors say the result cannot yet be assumed to hold for people who take the drug.

One molecule, two brand names, two hormone receptors

Tirzepatide is unusual among obesity drugs because it targets two gut-hormone receptors at once, GIP and GLP-1. The FDA approved it as Mounjaro on May 13, 2022, to improve blood sugar control in adults with type 2 diabetes, according to the agency’s Drug Trials Snapshot. On November 8, 2023, the agency announced its approval of the same drug as Zepbound for chronic weight management in adults with obesity, or with overweight and at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol.

Most of the weight loss seen with these drugs is attributed to reduced hunger and lower food intake. The Barcelona group asked a narrower question: whether the drug also changes fat tissue in ways that eating less cannot explain. The question matters because energy expenditure, not only intake, shapes how the body handles excess calories, and a drug that nudged both sides of that balance would work by more than one route.

Pair-fed mice as the control

According to the paper’s abstract, the team, whose authors include Alberto Mestres-Arenas, Tania Quesada-López, Albert Blasco-Roset, Marta Giralt, Francesc Villarroya, Anna Planavila and Peyrou, worked with male mice made obese on a high-fat diet. The treated animals received tirzepatide. Because the drug lowers appetite, a second group of untreated obese mice was given the same amount of food, so that any difference between the groups could be pinned on the drug rather than on the animals eating less.

The University of Barcelona’s news release describes the design in the same terms, comparing obese mice on high-fat diets treated with tirzepatide against untreated mice consuming identical portions. That pair-feeding control is the study’s main safeguard against the obvious objection that a leaner mouse simply has different fat to begin with.

Brown fat responds, white fat mostly does not

The paper reports “distinct effects on brown adipose tissue relative to white adipose tissues, significantly boosting thermogenic activity.” Brown fat, unlike white fat, is specialized for burning glucose and lipids to produce heat rather than storing them. In the tirzepatide-treated mice the tissue showed a greater capacity to burn metabolic energy, and the drug also improved glucose tolerance independently of how much the animals ate, the abstract says.

White fat behaved differently, with changes mainly in lipid metabolism, so the effect on brown fat was specific rather than a general shift across all fat depots, a distinction the abstract draws explicitly. The ScienceDaily write-up of the Barcelona release adds that activated brown fat produces “batokines,” signaling molecules that Peyrou described as beneficial for metabolism.

In the university’s release, Peyrou said the drug “activates brown adipose tissue,” a type of fat that specializes in burning calories from food. The team argued that the finding supports obesity strategies that both reduce food intake and raise energy expenditure, and that it could eventually inform more personalized treatment based on a patient’s overall metabolic status.

Limits of a mouse result

The authors set the limits themselves. The experiment used only male mice, and the abstract calls for human studies to determine whether the findings apply to people. Peyrou said in the release that because it is a mouse study, caution is needed, since “there may be significant differences between species in terms of metabolism regulation.”

That caution has practical weight. Nothing in the paper measures brown fat activity in patients taking Zepbound or Mounjaro, so the paper cannot say whether the mechanism contributes to the weight loss and metabolic improvements seen in the clinic, or how large any contribution might be. The mouse data describe a plausible route, and a plausible route is a hypothesis, not a finding about patients.

Whether a human version of the experiment gets run is the open question. Testing it would mean comparing brown fat activity in people on tirzepatide against people matched for the same weight loss, the human counterpart of the pair-fed mice, and the Barcelona paper provides the design rationale but no such data.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview